Paliperidone extended-release (ER) tablets, an investigational, once-daily oral medication for schizophrenia, improved sleep onset, sleep continuity, and duration of sleep in schizophrenia patients diagnosed with schizophrenia-related insomnia when compared with placebo, according to a press release from Janssen LP, based in Titusville, NJ. Data from this study were presented at the 19th Congress of the European College of Neuropsychopharmacology (ECNP).
“This is the first time a placebo-controlled study of this size was designed to specifically assess multiple parameters of sleep in a group of patients with schizophrenia who have specific complaints of insomnia,” said Remy Luthringer, PhD, lead investigator of the study. “In addition to the robust efficacy and tolerability profile observed in previously released data on paliperidone ER in the treatment of schizophrenia, we found in this study that patients receiving paliperidone ER fell asleep faster and stayed asleep longer than those on placebo. This suggests that paliperidone ER may provide an important additional benefit for the many patients with schizophrenia in whom sleep disturbance is a problem.”
For more information about Janssen, LP visit http://www.janssen.com/.